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Abstract
Background Pediatric renal replacement therapy (RRT) patients
surviving long-term are at a much higher risk of mortality com-
pared with the age-matched general population. Recently, we
demonstrated a transition from cardiovascular disease to infec-
tion as themain cause of death in a long-term follow-up study of
pediatric RRT. Here, we explore the burden of infections requir-
ing hospitalization over 30 years of follow-up on RRT.
Methods The cohort comprised all 234 Dutch patients on
RRT under 15 years of age between 1972 and1992. We ana-
lyzed infection-related hospitalizations during the period
1980–2010. We evaluated the Hospital Admission Rate
(HAR) per patient-years (py) and infectious over non-
infectious HAR ratio (HARR).
Results The HAR decreased significantly over time for all
patients. The rate of hemodialysis-related infections decreased
between 1980 and 1999, but stabilized during 2000–2010,
whereas peritoneal dialysis-related infections decreased pro-
gressively. Transplantation-related infections did not change,
except for urinary tract infections (UTIs), which increased
significantly from 3.3/100 py [95%CI 3.2–3.4] in 1980–
1989 to 4.4/100 py [4.2–4.5] in 2000–2010 (p <0.001). The
contribution of infection to HAR increased significantly in
transplanted patients (HARR: 1980–1989: 0.25 [0.2–0.3];
2000–2010: 1.0 [0.79–1.27], p <0.001).
Conclusions Our findings indicate a relative increase in infec-
tions requiring hospitalization over time in patients starting
RRT during the pediatric age, especially severe UTIs in trans-
plantation. More attention paid to urological abnormalities in
cases of recurrent UTI and tailored adjustment of immunosup-
pression may reduce risk in these patients.
Keywords Dialysis . Infections . Pyelonephritis . Renal
transplantation . Sepsis
Introduction
Patients starting renal replacement therapy (RRT) during the
pediatric age and surviving long term are at a much higher risk
of mortality compared with healthy peers, up to 30 times
greater, according to long-term outcome studies. By definition,
these data concern historical patients who underwent a different
approach compared with current practices. However, although
some data show a decline in death rates among end stage renal
disease (ESRD) children over time, a recent paper on ESPN/
ERA-EDTAdata showed a 55-fold increased risk in patientswith
pediatric ESRD compared with the general population [1–5].
Infection is one of the major causes of mortality and mor-
bidity in patients on RRT, accounting for the 15–23 % of
deaths in this population [6–8]. Various factors may contribute
to the high rate of life-threatening infections in these patients,
such as an impaired immune function as a result of decreased
renal function, the open connection of the peritoneal cavity in
patients on peritoneal dialysis (PD) and of the central venous
system in hemodialysis (HD) patients, and, above all, the use
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of immunosuppressive therapy in transplanted patients
[9–14]. It is of major concern that recent reports show an in-
creasing trend in infection-related mortality, both in dialysis and
transplanted patients, and not only in incident patients, but also
in patients with a long history of RRT, years after transplantation
[15, 16], with an infectious mortality rate increasing from 0.51/
100 patient-years (py) before 1989 to 0.82/100 py after 2000 in a
Dutch cohort [17]. Infection is one of the most frequent causes
of hospitalization in RRT patients [1, 9, 12, 18–23]. In adults it
has been associated with a 10 % death rate within 30 days of
admission [16]. Still, studies reporting the burden of severe non-
fatal infections in long-term RRT patients are lacking.
Our primary aim was therefore to evaluate the burden of
infections requiring hospitalization in patients starting RRT
during the pediatric age with a 30-year follow-up. Our sec-
ondary aim was to analyze the change in burden of severe
infections over time using infection-related hospitalization as
a marker. Lastly, as hospitalization patterns in the Netherlands
have adopted a higher threshold for admission over the last
30 years, we also analyzed the infection/non-infection admis-




We gathered information on patients from the Late Effects of
Renal Insufficiency Cohort (LERIC) study, which comprised
all Dutch patients who started chronic RRT between 1972 and
1992 at less than 15 years of age, and who were born before
1979. From the original LERIC cohort, we included all pa-
tients alive on 1 January 1980 (Fig. 1). Data collection details
and results of the first follow-up studies conducted on this
cohort between 1998 and 2000 have been described previous-
ly [1, 17]. In 2000 and 2010, coworkers from the LERIC study
visited all 37 hospitals that had been involved in the medical
care of patients during the observation period and collected
data on, amongst other things, age at RRT start, start and end
dates of HD, PD and transplantation, date and cause of death,
and the cause of each hospital admission. In living patients,
the day of review was considered to be the end of the obser-
vation period.
Hospital admissions
Information on any hospital admission between 1 January
1980 and the end of the observation period were collected.
Causes of hospitalization were classified independently by
three reviewers (JLV, JWG, and KJJ), using a detailed descrip-
tion of each patient status around the admission date. Admis-
sions for child birth, dialysis access placement and
transplantation were classified as Bplanned^ and excluded
from the analyses. Infection-related hospitalizations were clas-
sified as: airway infection, gastroenteritis, peritonitis, sepsis,
urinary tract infection (UTI), vascular access infection or other
infections. Other infections include all infections of unknown
origin. Furthermore, bacterial infections were defined as any
positive bacterial cultures, abscesses, UTIs, sepsis, tunnel/
central venous line infections, PD peritonitis (except when
indicated other), sinusitis, segmental pneumonia, bilateral
pneumonia with severe disease, pneumonia successfully treat-
ed with antibiotics, Bfever with chills and antibiotic
treatment.^ Infections defined as viral included all diagnoses
due to a specific virus, gastroenteritis except when indicated
as bacterial, and upper airway infection.
Statistical analysis
In this paper, we compare the rate of hospital admission and
infection-related admission during 2000–2010 with the previ-
ous two decades (1980–1989 and 1990–1999). The Hospital
Admission Rate (HAR) was calculated as the number of hos-
pital admissions per 100 py on RRT with a 95 % confidence
interval (95 % CI). Hospital Admission Rate Ratios (HARRs)
Fig. 1 Flow chart of the study cohort. Registry of patients on renal
replacement therapy (RENINE), Late Effects of Renal Insufficiency
Cohort (LERIC)
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were calculated to compare infection and non-infection-related
admissions. Poisson regression models were used to examine
the trends in infection and non-infection HARwith the decade
of admission (1980–1989, 1990–1999, and 2000–2010). In
the Poisson model, the natural logarithm of the total py at risk
was used as the offset. Data analysis was performed using R
(v. 3.0.1, R Foundation for Statistical Computing) [24].
Results
Study cohort
The total cohort consisted of 234 patients with a median
follow-up of 25.0 years (range 0.2–31.4). The median age at
the start of RRTwas 11.2 years (range 1.9–15.0), and 55.6 %
were female. The patient characteristics for each decade are
shown in Table 1. Between 2000 and 2010, 2 (1.4 %) patients
were lost to follow-up because of emigration, and 1 patient
(0.7 %) had avoided medical care since 2007.
All-cause hospital admission rates
A total of 2,563 hospital admissions were recorded, 757
(29.5 %) of which were infection-related. One thousand two
hundred and two admissions occurred between 1980 and
1989, 877 during 1990–1999, and 484 after the turn of the
century. Nearly all patients (224 out of 234) experienced at
least one unplanned admission during follow-up, with a me-
dian of 9 admissions per patient (range 1–100). Over the 30-
year period, the average HAR was 48.5/100 py (95 % CI:
48.3–48.7), i.e., almost once every 2 years. HAR was signif-
icantly higher in the 1980s (77.0 out of 100 py, 95%CI: 76.6–
77.5, p <0.0001) and 1990s (44.6 out of 100 py, 44.3–44.9, p
<0.0001) compared to 2000–2010 (27.6 out of 100 py, 27.3–
27.8). Figure 2 presents the trend in hospital admissions be-
tween 1980 and 2010 by decade and RRT modality.
Infection-related hospital admission rates
Infection-related HAR decreased between 1980–1989 and
1990–1999, but stabilized in 2000–2010. Infection-related
HAR in HD patients also decreased from 1980–1989 to
1990–1999, and stabilized after 2000, whereas infection-
related HAR in PD patients showed a progressive decrease
over time. Conversely, infection-related HAR in transplant
patients did not change significantly during the study period,
with an almost constant HAR from 11.9 during the 1980s to
9.9 out of 100 py during the 1990s and 2000s.
During the first year after transplantation, infection-related
HAR was consistently more frequent compared with the peri-
od after the first year. Furthermore, there was no improvement
over time for either the first-year risk, or the long-term risk of
infection-related admission, with a HAR in the 1980s of 30.7
(95 % CI: 29.8–31.5) for the first year vs 8.5 (95 % CI: 8.4–
8.7, p <0.0001) for later infections and 34.1 (95 % CI: 32.5–
35.8) vs 9.0 (95 % CI: 8.9–9.2, p <0.0001) during the 2000s
(Fig. 3).
Non-infection-related vs infection-related hospital
admission rate ratios
Compared with the rate of admissions for non-infectious
causes, the rate of infection-related admissions increased sig-
nificantly over time: the rate ratio over the 2000s was 0.73
(95 % CI: 0.61–0.88) vs 0.32 (95 % CI: 0.28–0.37, p <0.001)
and 0.42 (95 % CI: 0.36–0.49, p <0.001) for the 1980s and
1990s respectively. This rise was entirely due to a proportional
increase in infection-related admissions in transplant patients,
with an infection/non-infection ratio rising from 0.25 (95 %
CI: 0.20–0.30, p <0.001) between 1980 and 1989, to 0.50
(95 % CI: 0.41–0.60, p <0.001) between 1990 and 1999,
and up to 1 (95 % CI: 0.79–1.27) during the 2000s (Fig. 4).
Diagnosis-specific, infection-related hospital admission
rates
We classified infection-related admissions into specific diag-
nosis categories: airway infection, gastroenteritis, peritonitis,
sepsis, UTI, vascular access infections, and other Infections.
Of the 178 HD-related admissions due to infection, 30
(16.8 %) were airway infections, 28 (15.7 %) sepsis, 26
(14.6 %) vascular access infections, and 94 were other types
of infection. Rates of airway infection, sepsis, and other infec-
tions did not show any significant trend between 1980 and
2010; however, nearly all vascular access infections (21,
11.8 %) occurred during the 1980s (Fig. 5a).
Of the 155 PD-related admissions due to infection, perito-
nitis was by far the most common cause of admission (111,
71.6%). The peritonitis-specific admission rate remained con-
stant throughout the follow-up period (Fig. 5b); however, we
found a significant increase in peritonitis/other infection ratio
from the 1980s (1.4, 95 % CI: 1.3–1.5) to the later decades
(3.2, 95 % CI: 3.0–3.5 in the 2000s).
In the 422 transplant-related patients admitted because of
infection, the most common forms were UTI (149, 35.3 %),
airway infection (61, 14.5%), and gastroenteritis (66, 15.6%).
In particular, the admission rate due to UTI showed an in-
crease over the decades (Fig. 5c). The majority of UTIs oc-
curred in transplant patients affected by congenital abnormal-
ities of the kidney and urinary tract (CAKUT; HAR was 4.8
out of 100 py, 95 %CI: 4.6–5.0; 3.9 out of 100 py, 95 % CI:
3.7–4.1, and 5.6 out of 100 py, 95 % CI: 5.3–5.8 during the
three study decades respectively), which was higher compared
with patients with other renal diseases (HAR 2.6 out of 100
py, 95 % CI: 2.5–2.7; 2.9 out of 100 py, 95 % CI: 2.8–3.0, and
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Table 1 Characteristics of the study population at specific time points during the 30-year follow-up
1 January 1980 (%) 1 January 1990 (%) 1 January 2000 (%) 1 January 2010 (%) Total
Number of patients 95 199 185 152 234
Male (%) 39 (41.05) 88 (44.22) 83 (44.86) 71 (46.71) 104 (44.4)
Patients’ age (years) 14.53 (3.60–21.88) 19.48 (11.01–31.88) 29.42 (21.01–41.50) 39.30 (31.01–51.50) –
CAKUT patients (%) 29 (30.53) 64 (32.16) 62 (33.51) 52 (34.21) 77 (32.91)
Age at RRT (years) 11.00 (1.88– 14.94) 11.25 (1.88–15.87) 11.62 (1.88–21.33) 11.74 (1.88–21.33) 11.39 (1.88–21.33)
Patients on hemodialysis (%) 28 (29.5) 33 (16.6) 23 (12.4) 24 (15.8) –
Hemodialysis time (years)a 1.21 (0.13–6.40) 1.82 (0.03–15.63) 2.23 (0.03–25.63) 2.31 (0.03–35.63) 2.79 (0.03–36.52)
Number of HD
Patients with at least 1 HD 28 (100) 111 (69.8) 93 (53.4) 90 (49.2) 87 (47.5)
Patients with at least 2 HD 0 (0.0) 35 (22) 47 (27) 50 (27.3) 52 (28.4)
Patients with at least 3 HD 0 (0.0) 11 (6.9) 28 (16.1) 28 (15.3) 29 (15.8)
Patients with more than 3 HD 0 (0.0) 2 (1.3) 6 (3.4) 15 (8.2) 15 (8.2)
Patients on peritoneal dialysis (%) 0 (0.0) 10 (5.0) 18 (9.7) 4 (2.6) –
Peritoneal dialysis in time (years)b 0.04 (0.02–5) 1.03 (0.01–10.73) 1.62 (0.01–15.36) 2.13 (0.01–10.73) 2.42 (0.08–18.55)
Number of PD
Patients with at least 1 PD 0 (0.0) 47 (92.2) 54 (67.5) 59 (65.6) 62 (66.7)
Patients with at least 2 PD 0 (0.0) 4 (7.8) 22 (27.5) 25 (27.8) 25 (26.9)
Patients with at least 3 PD 0 (0.0) 0 (0.0) 4 (5) 4 (4.4) 4 (4.3)
Patients with more than 3 PD 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.2) 2 (2.2)
Patients on transplantation (%) 67 (70.5) 156 (78.4) 144 (77.8) 124 (81.6) -
Transplantation time (years)c 2.05 (0.01–9.05) 5.77 (0.01–19.06) 13.93 (0.13–29.05) 20.20 (0.01–39.65) 23.43 (0.19–39.06)
Number of TX
Patients with at least 1 TX 67 (100) 95 (67.9) 104 (57.8) 87 (39.5) 86 (39.1)
Patients with at least 2 TX 0 (0.0) 39 (27.9) 59 (32.8) 83 (37.7) 84 (38.2)
Patients with at least 3 TX 0 (0.0) 6 (4.3) 13 (7.2) 41 (18.6) 41 (18.6)
Patients with more than 3 TX 0 (0.0) 0 (0.0) 4 (2.2) 9 (4.1) 9 (4.1)
CAKUT congenital abnormalities of kidney and urinary tract, RRT renal replacement therapy, HD hemodialysis, PD peritoneal dialysis, TX
transplantation
a Patients with at least one period on HD
b Patients with at least one period on PD
c Patients with at least one period on TX
Fig. 2 Hospital admission
incidence rate for infection and
non-infection-related causes by
decade and renal replacement
therapy (RRT) modality. Inside
the bars hospital admission
incidence rates with 95 %
confidence interval (CI) are
presented. HD hemodialysis, PD
peritoneal dialysis, TX
transplantation
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3.8 out of 100 py, 95 % CI: 3.6–3.9 in the three study decades
respectively, p=0.014). This increase was not due to an in-
crease in the proportion of CAKUT patients over time, as
shown in Table 1. In these patients, UTI in the first year after
transplantation was significantly more frequent than later in
the 2000s (HAR 18.1 out of 100 py, 95%CI: 16.9–19.3 vs 3.6
out of 100 py, 95 % CI: 3.5–3.8, p <0.001), and in the 1980s
(HAR 7.8 out of 100 py, 95%CI: 7.4–8.3 vs 2.7 out of 100 py,
95 % CI: 2.6–2.9, p=0.005), but not in the 1990s. Further-
more, as expected, we found a large difference between the
rate of UTI in male (HAR 8.5 out of 100 py, 95% CI: 8.2–8.8;
6.0 out of 100 py, 95 % CI: 5.8–6.2, and 9.8 out of 100 py,
95%CI: 9.5–10.1 in the three study decades respectively) and
female patients (HAR 0.7 out of 100 py, 95 % CI: 0.6–0.8; 1.8
out of 100 py, 95 % CI: 1.7–1.9, and 1.7 out of 100 py, 95 %
CI: 1.6–1.8 in the three study decades respectively, p <0.01),
and this difference was significant both for CAKUT (p=
0.005) and for non-CAKUT patients (p=0.02).
Of the 757 infection-related admissions recorded during
the study period, 482 (63.7 %) were classified as bacterial,
163 (21.5 %) as viral, and 15 (1.9 %) as fungal or due to
mycoplasma, while 95 (12.5 %) were of unknown origin.
We found no significant trends in bacterial infections (chang-
ing from a HAR of 5.9 out of 100 py, 95 % CI: 5.8–6.1 in the
1980s to 6.8 out of 100 py, 95 % CI: 6.6–6.9 in the 2000s, p=
0.213), whereas the number of viral infections significantly
decreased over time, from 3.7 out of 100 py, 95 % CI: 3.6–
3.8 in the 1980s to 2.9 out of 100 py, 95 % CI: 2.8–3.1 in the
2000s (p=0.021).
Discussion
We analyzed the burden of severe infections over 30 years of
RRT in patients with pediatric onset of RRT using hospitali-
zations as a marker. We found a consistent increase in the
Fig. 3 Hospital admissions
incidence rate for infection in the
first year and later after renal
transplantation. Error bars
represent 95 % CI
Fig. 4 Infection/non-infection
Hospital Admission Rate Ratio
(HARR) according to decade and
RRT modality. *p <0.001 vs the
decade 2000–2010. Whiskers
represent 95 % CI. HD
hemodialysis, PD peritoneal
dialysis, TX transplantation
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infection/non-infection HARR, suggesting an increase in the
relative contribution of infections to hospital admissions over
the past decades. This increase was exclusively found in pa-
tients living with a functioning renal graft, where UTIs
accounted for the majority of admissions.
Very few data exist on the long-term effects of RRT, as
most studies report on data covering much shorter periods of
observation. Our data show a high burden of transplant-related
infections, not only during the first year after transplantation,
as previously described by others [25–28], but also long after-
ward. We found no significant changes in the first year/later
infection ratio throughout the observation period. This is es-
pecially remarkable as these patients were on average between
30 and 40 years old in 2000–2010, an age that is associated
with the lowest risk of death by infection according to most
RRT registry studies [29, 30]. Our findings, therefore, most
probably reflect a more general trend toward a relative in-
crease in infections in renal transplant patients over the last
10 years. This trend is in line with the shift from cardiovascu-
lar to infectious disease as the primary cause of death, on
which we previously reported [17], as well as with reports
on admission rates for infections during the first post-
transplant year [15, 25, 29, 31, 32].
Infections, even if not lethal, are especially worrying in
transplantation patients as they may lead to graft loss. UNOS
data have shown an increase in death-censored graft failures
due to infections between 1997 and 2006 from 6.4 to 10.1 %
[33]. Infection may lead to graft failure in several ways. It may
activate the immune system and trigger cytokines that may
induce interstitial inflammation, leading to chronic allograft
nephropathy. BK and CMV viruses may cause tubulo-
interstitial nephritis and bacterial pyelonephritis, and may also
directly damage the renal graft [21]. According to the UNOS
data, UTIs related to urological complications were associated
with an 8.8-times increased risk of death-censored graft failure
[33].
The most plausible cause for the increase in burden of
transplant-related infections is the concurrent tendency toward
the use of more potent immunosuppressive strategies in renal
transplantation over the last 20 years [34]. There is abundant
evidence for a direct relationship between the extent of immu-
nosuppression after transplantation and the risk of infection
[31, 35, 36]. It is not the specific type of drug, but the use of
higher dosages, especially of calcineurin inhibitors, and the
use of triple instead of double therapy, that have been found
to be associated with both a decrease in acute rejections and,
as a tradeoff, more infections, such as polyomavirus and UTI
[37–40]. In the Netherlands, and similarly inmany other coun-
tries, all centers for adult renal transplantation introduced IL-2
blockers during the early 2000s as part of induction therapy,
and all centers have switched from cyclosporine to high-dose
tacrolimus in combination with mycophenolate mofetil as part
of induction therapy. Indeed, this implies a substantial in-
crease in the average immunosuppressive dose over the last
10 years [34]. A Spanish observational study showed that
basiliximab as part of induction therapy was associated with
UTI after renal transplantation [28]. The observed rise in hos-
pital admissions related to UTI in transplantation patients may
320 Pediatr Nephrol (2016) 31:315–323
Fig. 5 Hospital Admission Rate (HAR) for the most frequent type of infections according to renal replacement therapy (RRT)modality. aHemodialysis;
b peritoneal dialysis; c renal transplantation. Error bars represent 95 % CI
also be due to the increasing use of antibiotic prophylaxis after
renal transplantation, causing a rise in multi-resistant infec-
tions that frequently require intravenous antibiotic treatment
and hospitalization [40, 41]. In addition, a general increase in
the incidence of infections in Western countries has been re-
ported, possibly due to several factors, such as an increase in
multi-resistant infection incidence and improved detection
and reporting practices [35, 42, 43].
For PD, we observed a gradual decrease over time in
infection-related admissions, except for peritonitis. The
persisting burden of PD-related peritonitis contrasts with data
from two European centers, an Australian center and a Cana-
dian Registry, all showing a decreasing trend over time
[44–47]. An explanation might be that these studies analyzed
different patients in different eras in contrast to ours, where we
followed one closed cohort of patients over time. In these
studies, profiles of patients within the different eras did not
vary significantly in duration of RRT and, consequently, co-
morbidity, whereas in our study, patients who were on PD in
the decade 2000–2010 had, by definition, more years of RRT
and a greater dialysis burden than in the years before. Con-
versely, those surviving to 2000–2010 may be considered less
susceptible to various peritonitis risk factors as they can be
considered Bsurvivors^. Therefore, this finding raises concern,
especially as it is also at odds with the major reduction in
vascular access-related infections seen in HD over time.
This study has several limitations. First, we used hospitali-
zation as a marker for the burden of severe infections. Hospi-
talization has been used as an indicator of disease severity for
various other diseases, as severity assessment scores may have
even more limitations [48–50]. Changes in hospitalization rates
over time are fraught with difficulties because they may be
subject to underlying trends in patterns of care. A change in
the rate of hospitalizations not only reflects disease severity or
incidence, but also organizational issues, such as improved
methods of outpatient care, a change in the diagnostic criteria
for infections, and changes in nephrologist hospitalization and
treatment policies from the 1980s up to the present day. In
Europe, there is a general trend toward lower numbers and
shorter hospital stays. This is clearly reflected in the decreasing
number of non-infectious-related hospitalizations. Therefore,
the relatively constant rate of infectious hospitalizations may
even be flawed, as in reality there may have been a sharp in-
crease in the number of infections, but patients were not admit-
ted to hospital. Another limitation is the retrospective collection
of the data, which in some cases hampered an accurate distinc-
tion between bacterial and other causes of infection. Finally,
following a closed cohort of patients over such a long period,
patients surviving up to 2000 after a long history of RRT may
represent a very specific population that may be difficult to
compare with all prevalent RRT patients. For instance, patients
returning to dialysis after transplant failure could be at a higher
risk of infection than naïve dialysis patients.
In short, we found evidence for a significant increase in the
burden of clinically significant infections in transplanted pa-
tients over the past decades, not only in the first year after
transplantation, but also among patients who have been living
with a functioning graft for a prolonged period of time. This
high risk of infection should be taken into account in the
management of patients with a long history of RRT, such as
a more tailored down immunosuppressive regimen in patients
with no history of rejection and the specific analysis of uro-
logical function in patients with recurrent UTI.
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